A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
Authors:
- Domenico SabatiniDSDomenico Sabatini
- Brunella CapaldoBCBrunella Capaldo
- Carlo VigoritoCVCarlo Vigorito
- Arturo GiordanoAGArturo Giordano
- Raffaele GuidaRGRaffaele Guida
- Francesco PardoFPFrancesco Pardo
- Bernadette BiondiBBBernadette Biondi
- Luigi SaccàLSLuigi Saccà
Open Access
- 28 March 1996
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 334 (13) , 809-814
Abstract
Cardiac hypertrophy is a physiologic response that allows the heart to adapt to an excess hemodynamic load. We hypothesized that inducing cardiac hypertrophy with recombinant human growth hormone might be an effective approach to the treatment of idiopathic dilated cardiomyopathy, a condition in which compensatory cardiac hypertrophy is believed to be deficient. Seven patients with idiopathic dilated cardiomyopathy and moderate-to-severe heart failure were studied at base line, after three months of therapy with human growth hormone, and three months after the discontinuation of growth hormone. Standard therapy for heart failure was continued throughout the study. Cardiac function was evaluated with Doppler echocardiography, right-heart catheterization, and exercise testing. When administered at a dose of 14 IU per week, growth hormone doubled the serum concentrations of insulin-like growth factor I. Growth hormone increased left-ventricular-wall thickness and reduced chamber size significantly. Consequently, end-systolic wall stress (a function of both wall thickness and chamber size) fell markedly (from a mean [±SE] of 144±11 to 85±8 dyn per square centimeter, P<0.001). Growth hormone improved cardiac output, particularly during exercise (from 7.4±0.7 to 9.7±0.9 liters per minute, P = 0.003), and enhanced ventricular work, despite reductions in myocardial oxygen consumption (from 56±6 to 39±5 ml per minute, P = 0.005) and energy production (from 1014±100 to 701±80 J per minute, P = 0.002). Thus, ventricular mechanical efficiency rose from 9±2 to 21±5 percent (P = 0.006). Growth hormone also improved clinical symptoms, exercise capacity, and the patients' quality of life. The changes in cardiac size and shape, systolic function, and exercise tolerance were partially reversed three months after growth hormone was discontinued. Recombinant human growth hormone administered for three months to patients with idiopathic dilated cardiomyopathy increased myocardial mass and reduced the size of the left ventricular chamber, resulting in improvement in hemodynamics, myocardial energy metabolism, and clinical status.Keywords
This publication has 35 references indexed in Scilit:
- Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction.Journal of Clinical Investigation, 1995
- Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathyAmerican Heart Journal, 1991
- Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathyAmerican Heart Journal, 1988
- A Hyperkinetic Heart in Uncomplicated Active AcromegalyActa Medica Scandinavica, 1988
- Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application.Circulation, 1982
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978
- In vivo validation of a thermodilution method to determine regional left ventricular blood flow in patients with coronary disease.Circulation, 1978
- Left ventricular mechanical efficiency in man with heart disease.Circulation, 1977
- Effect of Supine Exercise on Left Ventricular Volume and Oxygen Consumption in ManCirculation, 1965
- The Effect of Exercise on Coronary Blood Flow, Myocardial Oxygen Consumption and Cardiac Efficiency in ManCirculation, 1953